DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: Impact on treatment efficacy and toxicity

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 1, 2011, Pages 49-56

  Yang, Chen Guang ^a   Ciccolini, Joseph ^a   Blesius, Aurore ^a   Dahan, Laetitia ^a   Bagarry Liegey, Danielle ^a   Brunet, Caroline ^a   Varoquaux, Arthur ^a   Frances, Nicolas ^b   Marouani, Hafedh ^b   Giovanni, Antoine ^a   Ferri Dessens, Rose Marie ^c   Chefrour, Mohamed ^b   Favre, Roger ^a   Duffaud, Florence ^a   Seitz, Jean François ^a   Zanaret, Michel ^a   Lacarelle, Bruno ^a   Mercier, Cédric ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Roche   (France)

Author keywords

5 Fluorouracil; Dose tailoring; DPD; Efficacy; Head and neck cancer; Toxicity

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ADULT; AGE; AGED; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78651086494     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1282-4     Document Type: Article

References (36)

1. GP Browman C Cripps DI Hodson L Eapen J Sathya MN Levine 1994 Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer J Clin Oncol 12 2648 2653 1:STN:280:DyaK2M%2FotFyjtA%3D%3D 7989940
2. W Budach T Hehr V Budach C Belka K Dietz 2006 A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck BMC Cancer 6 28 1:CAS:528:DC%2BD28XjtFCmtbg%3D 10.1186/1471-2407-6-28 16448551
3. N Choong E Vokes 2008 Expanding role of the medical oncologist in the management of head and neck cancer CA Cancer J Clin 58 32 53 10.3322/CA.2007.0004 18096865
4. D Chua WI Wei JS Sham GK Au 2008 Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer Jpn J Clin Oncol 38 244 249 10.1093/jjco/hyn022 18407933 (Pubitemid 351583987)
5. J Ciccolini C Mercier L Dahan A Evrard JC Boyer K Richard JP Dales A Durand G Milano JF Seitz B Lacarelle 2006 Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine dehydrogenase deficiency Cancer Chemother Pharmacol 58 272 275 1:CAS:528:DC%2BD28XjvFGitrw%3D 10.1007/s00280-005-0139-8 16292536
6. J Ciccolini C Mercier A Evrard L Dahan JC Boyer F Duffaud K Richard C Blanquicett G Milano A Blesius A Durand JF Seitz R Favre B Lacarelle 2006 A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy Ther Drug Monit 28 678 685 1:CAS:528:DC%2BD28XhtVKrtL3L 10.1097/01.ftd.0000245771.82720.c7 17038885 (Pubitemid 44564069)
7. R Fety F Rolland M Barberi-Heyob A Hardouin L Campion T Conroy JL Merlin A Riviere G Perrocheau MC Etienne G Milano 1998 Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas Clin Cancer Res 4 2039 2045 1:CAS:528:DyaK1cXmslCjsrg%3D 9748117
8. JF Fowler MJ Lindstrom 1992 Loss of local control with prolongation in radiotherapy Int J Radiat Oncol Biol Phys 23 457 467 1:STN:280: DyaK383msl2isA%3D%3D 10.1016/0360-3016(92)90768-D 1534082
9. R Hitt A Lopez-Pousa J Martinez-Trufero V Escrig J Carles A Rizo D Isla ME Vega JL Marti F Lobo P Pastor V Valenti J Belon MA Sanchez C Chaib C Pallares A Anton A Cervantes L Paz-Ares H Cortes-Funes 2005 Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer J Clin Oncol 23 8636 8645 10.1200/JCO.2004.00.1990 16275937 (Pubitemid 46211506)
10. R Hitt L Paz-Ares A Brandariz D Castellano C Pena JM Millan F Calvo D Ortiz de Urbina E Lopez JJ Alvarez-Vicent H Cortes-Funes 2002 Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial Ann Oncol 13 1665 1673 1:STN:280:DC%2BD38nitVajsw%3D%3D 10.1093/annonc/mdf268 12377658 (Pubitemid 35331467)
11. Innocenti F (ed) (2009) Genomics and pharmacogenomics in anticancer drug development and clinical response. Humana Press, Totowa
12. C Jacobs G Lyman E Velez-Garcia KS Sridhar W Knight H Hochster LT Goodnough JE Mortimer LH Einhorn L Schacter, et al. 1992 A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck J Clin Oncol 10 257 263 1:STN:280:DyaK387itF2gtA%3D%3D 1732427
13. MR Johnson A Hageboutros K Wang L High JB Smith RB Diasio 1999 Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil Clin Cancer Res 5 2006 2011 1:STN:280:DyaK1MvgtVSmug%3D%3D 10473079
14. DB Longley DP Harkin PG Johnston 2003 5-fluorouracil: mechanisms of action and clinical strategies Nat Rev Cancer 3 330 338 1:CAS:528: DC%2BD3sXjtlals70%3D 10.1038/nrc1074 12724731 (Pubitemid 37328853)
15. C Mercier J Ciccolini 2006 Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy Clin Colorectal Cancer 6 288 296 1:CAS:528:DC%2BD2sXhsVSmtrs%3D 10.3816/CCC.2006.n.047 17241513
16. C Mercier C Yang J Ciccolini M Balti A Evrard A Blesius L Dahan K Richard J Seitz B Lacarelle R Favre 2006 Determination of uracil/UH2 ratio as a potential surrogate for DPD status in cancer patients presenting with severe toxicities during fluoropyrimidine treatment J Clin Oncol 24 2020 Meeting Abstracts
17. G Milano AL Chamorey 2002 Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics Chronobiol Int 19 177 189 1:CAS:528:DC%2BD38XjsFWjtLo%3D 10.1081/CBI-120002597 11962674 (Pubitemid 34310826)
18. WB Parker YC Cheng 1990 Metabolism and mechanism of action of 5-fluorouracil Pharmacol Ther 48 381 395 1:CAS:528:DyaK3MXkt1Wns7w%3D 10.1016/0163-7258(90)90056-8 1707544
19. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 15761078
20. LJ Peters HR Withers 1997 Applying radiobiological principles to combined modality treatment of head and neck cancer-the time factor Int J Radiat Oncol Biol Phys 39 831 836 1:STN:280:DyaK1c%2FjsVSlsQ%3D%3D 10.1016/S0360-3016(97) 00466-5 9369130 (Pubitemid 27486070)
21. MR Posner DM Hershock CR Blajman E Mickiewicz E Winquist V Gorbounova S Tjulandin DM Shin K Cullen TJ Ervin BA Murphy LE Raez RB Cohen M Spaulding RB Tishler B Roth C Viroglio Rdel V Venkatesan I Romanov S Agarwala KW Harter M Dugan A Cmelak AM Markoe PW Read L Steinbrenner AD Colevas CM Norris Jr RI Haddad 2007 Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 1705 1715 1:CAS:528:DC%2BD2sXht1ansLvI 10.1056/NEJMoa070956 17960013 (Pubitemid 350005152)
22. PH Roos HM Bolt 2005 Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1 Expert Opin Drug Metab Toxicol 1 187 202 1:CAS:528:DC%2BD2MXhtVKltLbL 10.1517/17425255.1.2.187 16922636
23. J Santini G Milano A Thyss N Renee P Viens P Ayela M Schneider F Demard 1989 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer Br J Cancer 59 287 290 1:STN:280:DyaL1M7psVSlug%3D%3D 2930694
24. M Schneider MC Etienne G Milano A Thyss J Otto O Dassonville H Mobayen L Saudes T Guillot F Demard 1995 Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey J Clin Oncol 13 1656 1662 1:STN:280:DyaK2MzisFyrsQ%3D%3D 7602355
25. PM Specenier JB Vermorken 2007 Neoadjuvant chemotherapy in head and neck cancer: should it be revisited? Cancer Lett 256 166 177 1:CAS:528: DC%2BD2sXhtVOisLrF 10.1016/j.canlet.2007.06.015 17673364 (Pubitemid 47418352)
26. PM Specenier JB Vermorken 2008 Recurrent head and neck cancer: current treatment and future prospects Expert Rev Anticancer Ther 8 375 391 1:CAS:528:DC%2BD1cXjvF2ltbs%3D 10.1586/14737140.8.3.375 18366286 (Pubitemid 351836286)
27. S Sumi K Kidouchi S Ohba Y Wada 1995 Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography J Chromatogr B Biomed Appl 672 233 239 1:CAS:528: DyaK2MXovVyntL8%3D 10.1016/0378-4347(95)00228-B 8581129
28. A Thyss G Milano N Renee J Vallicioni M Schneider F Demard 1986 Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer Cancer Chemother Pharmacol 16 64 66 1:STN:280:DyaL28%2Fltlyguw%3D%3D 10.1007/BF00255288 3940221
29. DL Trump MJ Egorin A Forrest JK Willson S Remick KD Tutsch 1991 Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole J Clin Oncol 9 2027 2035 1:STN:280:DyaK38%2FksVOiug%3D%3D 1941062
30. AB van Kuilenburg EW Muller J Haasjes R Meinsma L Zoetekouw HR Waterham F Baas DJ Richel AH van Gennip 2001 Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G > A mutation causing DPD deficiency Clin Cancer Res 7 1149 1153 11350878
31. JB Vermorken E Remenar C van Herpen T Gorlia R Mesia M Degardin JS Stewart S Jelic J Betka JH Preiss D van den Weyngaert A Awada D Cupissol HR Kienzer A Rey I Desaunois J Bernier JL Lefebvre 2007 Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 1695 1704 1:CAS:528:DC%2BD2sXht1ansLvP 10.1056/NEJMoa071028 17960012 (Pubitemid 350005151)
32. EE Vokes R Mick MS Kies ME Dolan D Malone I Athanasiadis DJ Haraf M Kozloff RR Weichselbaum MJ Ratain 1996 Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer J Clin Oncol 14 1663 1671 1:CAS:528:DyaK28XjtFKitr4%3D 8622086
33. CM Walko HL McLeod 2008 Will we ever be ready for blood level-guided therapy? J Clin Oncol 26 2078 2079 10.1200/JCO.2007.14.9609 18445837
34. J Wihlm D Leveque M Velten T Klein 1993 Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion Bull Cancer 80 439 445 1:STN:280:DyaK2c3islersA%3D%3D 8173197
35. FP Worden J Moon W Samlowski JI Clark SR Dakhil S Williamson SG Urba J Ensley MH Hussain 2006 A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007 Cancer 107 319 327 1:CAS:528:DC%2BD28Xnsl2mtLg%3D 10.1002/cncr.21994 16779801 (Pubitemid 44036561)
36. M Boisdron-Celle G Remaud S Traore AL Poirier L Gamelin A Morel E Gamelin 2007 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency Cancer Lett 249 271 282 1:CAS:528:DC%2BD2sXjsVekur8%3D 10.1016/j.canlet.2006.09. 006 17064846 (Pubitemid 46452935)